# Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.

Study · id `cardio:ct-nct05720572` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05720572](<https://clinicaltrials.gov/study/NCT05720572>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05720572

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 105 participants.

## Technical summary

Registry record NCT05720572. Randomized; triple masking; primary purpose treatment. Start 2019-09-01 (actual); primary completion 2025-09-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 105 participants (planned count; ClinicalTrials.gov record NCT05720572, source copy `cardio:ctgov-nct05720572-2023-02-14`, retrieved 2026-10-26)
- Started: 2019-09-01 (actual) (ClinicalTrials.gov record NCT05720572, source copy `cardio:ctgov-nct05720572-2023-02-14`, retrieved 2026-10-26)
- Primary completion: 2025-09-01 (anticipated) (ClinicalTrials.gov record NCT05720572, source copy `cardio:ctgov-nct05720572-2023-02-14`, retrieved 2026-10-26)
- Completion: 2026-01-01 (anticipated) (ClinicalTrials.gov record NCT05720572, source copy `cardio:ctgov-nct05720572-2023-02-14`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT05720572, source copy `cardio:ctgov-nct05720572-2023-02-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05720572-2023-02-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Antazoline in Comparison to Propafenone in Pharmacological Cardioversion of Atrial Fibrillation.
- Acronym: AnProAF
- Condition: Atrial Fibrillation
- Intervention (Drug): Antazoline
- Intervention (Drug): Propafenone
- Lead sponsor: Centre of Postgraduate Medical Education
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: bbdebeb266020c413d3ccecd11da945f304274beb29eb82556eee01082d19c80
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
